GGrantIndex
← Leaderboards

Amrita Krishnan

University Of Southern California

$301,778
Attributed
$301,778
Total exposure
13
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $39K · FY200509
$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$301,778 · 13

By mechanism

M01$301,778 · 13

Top collaborators

No co-investigators on record.

Most similar at University Of Southern California

Same institution · by research overlap

Others in their field

Top investigators on “Hematopoietic Stem Cells

Research focus

Hematopoietic Stem CellsClinical ResearchHuman Therapy EvaluationHuman SubjectRibozymesClinical TrialsHematopoietic Tissue TransplantationNeoplasm /Cancer ChemotherapyTissue /Cell CultureAids TherapyNonhodgkin'S LymphomaTransfection /Expression VectorColony Stimulating FactorHomologous TransplantationResearch PersonnelResourcesRetroviridaeGene TherapyEtoposideGrantNeoplasm /Cancer ImmunotherapyFundingCombination Cancer TherapyComputer Retrieval Of Information On Scientific Projects Database

Grant awards (18)

PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS$7,569
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$1,201
M01 · FY2008 · RR · contact PI
A PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS$1,106
M01 · FY2008 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$3,875
M01 · FY2007 · RR · contact PI
PHASE I CLINICAL TRIAL OF 17-ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN (KOS-953)$968
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$33,748
M01 · FY2006 · RR · contact PI
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO$3,025
M01 · FY2006 · RR · contact PI
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469$2,178
M01 · FY2006 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$24,791
M01 · FY2005 · RR
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469$6,198
M01 · FY2005 · RR
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO$4,305
M01 · FY2005 · RR
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO...$19,349
M01 · FY2004 · RR
RIBOZYMES IN PERIPHERAL BLOOD PROGENITOR CELLS$2,148
M01 · FY2004 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2002 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$155,764
M01 · FY2001 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2001 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$35,553
M01 · FY2000 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2000 · RR